What this deck covers
This deck focuses on Recognition And Management, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Study Recognition And Management in NAPLEX with focused flashcards that help you recognize the idea, recall the key rule, and apply it in practice-style prompts.
0% Complete
What is the primary management approach for neuroleptic malignant syndrome?
Tap card or press Space to flip
Stop antipsychotic; supportive care. Discontinues the offending agent while providing cooling, hydration, and monitoring for complications.
How well did you know it?
Card 1 / 25
Space to flip · ← / → to move · once flipped, → Got it · ← Still learning
This deck focuses on Recognition And Management, giving you a quick way to review the definitions, rules, and examples that matter most for NAPLEX.
Work through these flashcards in short sessions. Try to answer each prompt before flipping the card, then revisit any cards you miss until the explanation feels automatic.
Answer: Stop antipsychotic; supportive care. Discontinues the offending agent while providing cooling, hydration, and monitoring for complications.
Answer: Cyproheptadine. Functions as a serotonin 5-HT2A receptor antagonist to mitigate hyperstimulation symptoms.
Answer: Hypotension, bronchospasm, urticaria/angioedema. Represents multisystem involvement in severe IgE-mediated hypersensitivity reaction.
Answer: Cholinergic (organophosphate) toxidrome. Stems from acetylcholinesterase inhibition leading to excessive muscarinic and nicotinic stimulation.
Answer: Anticholinergic toxidrome. Arises from muscarinic blockade causing decreased secretions, hyperthermia, and altered mental status.
Answer: Give glucagon or IV dextrose. Quickly restores blood glucose to prevent neuronal damage and reverse altered consciousness.
Answer: Inhaled SABA plus systemic corticosteroid. SABA induces rapid bronchodilation, while corticosteroids suppress airway inflammation.
Answer: Neuroleptic malignant syndrome. Occurs as an idiosyncratic reaction to dopamine blockade causing muscle rigidity and rhabdomyolysis.
Answer: Serotonin syndrome. Arises from excessive serotonin leading to neuromuscular excitation and autonomic hyperactivity.
Answer: IV fluids and broad-spectrum antibiotics. Provides volume resuscitation for shock and empiric coverage against likely pathogens.
Answer: Naloxone. Acts as a competitive mu-opioid receptor antagonist to restore ventilation.
Answer: N-acetylcysteine. Replenishes glutathione to neutralize the toxic NAPQI metabolite and prevent liver damage.
Answer: IV calcium (gluconate or chloride). Stabilizes cardiac cell membranes by antagonizing potassium's depolarizing effects.
Answer: Insulin with dextrose. Insulin activates Na/K-ATPase to drive potassium into cells, with glucose preventing hypoglycemia.
Answer: Prolonged QT interval. Reflects delayed ventricular repolarization predisposing to polymorphic ventricular tachycardia.
Answer: Activate emergency response and urgent imaging. Facilitates rapid diagnosis and time-sensitive interventions like thrombolysis for ischemic stroke.
Answer: Activated charcoal. Adsorbs toxins in the GI tract to limit systemic absorption if given soon after ingestion.
Answer: IM epinephrine. Rapidly reverses hypotension, bronchospasm, and angioedema via alpha and beta adrenergic receptor stimulation.
Answer: Chronic benzodiazepine use or seizure risk. Risks precipitating withdrawal seizures in dependent users or those with seizure predisposition.
Answer: IV magnesium sulfate. Suppresses early afterdepolarizations and stabilizes potassium channels in prolonged QT states.
Answer: Respiratory alkalosis plus anion gap metabolic acidosis. Initial respiratory stimulation causes alkalosis, followed by uncoupling-induced metabolic acidosis.
Answer: Opioid toxidrome. Results from mu-opioid receptor agonism depressing respiratory drive and CNS function while constricting pupils.
Answer: Hyperkalemia. Elevated extracellular potassium alters cardiac repolarization and conduction on ECG.
Answer: Flumazenil. Competitively antagonizes benzodiazepine binding at GABA_A receptors to reverse sedation.
Answer: Atropine and pralidoxime. Atropine competitively inhibits muscarinic receptors, while pralidoxime regenerates acetylcholinesterase.